Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Jun 4;24(10):2003–2008. doi: 10.1016/j.bbmt.2018.05.027

Table 1.

Patient characteristics by presence or absence of any chromosomal aberration

With aberration (N=16) Without aberration (N=57)
N % N % P
Patient-related
Age, years 0.17
 <10 4 25.0% 27 47.4%
 10-<20 9 56.3% 26 45.6%
 20 or older 3 18.8% 4 7.0%
Race 0.27
 Caucasian 15 93.8% 45 78.9%
 Other 1 6.3% 12 21.1%
Karnofsky Performance Score1 0.07
 10–80 4 25.0% 4 7.1%
 90–100 12 75.0% 52 92.9%
Transplant-related
Months from SAA diagnosis to HCT2 0.32
 <36 4 30.8% 24 42.1%
 36-<72 3 23.1% 19 33.3%
 ≥72 months 6 46.2% 14 24.6%
Graft type, Bone marrow 15 93.8% 48 84.2% 0.44
Conditioning regimen 0.44
 Myeloablative 7 43.8% 16 28.1%
 Reduced intensity/Nonmyeloablative 9 56.3% 38 66.7%
 Other 0 0% 3 5.3%
GvHD prophylaxis 0.68
 Ex vivo T-cell depletion 10 62.5% 35 61.4%
 Tacrolimus-based 1 6.3% 2 3.5%
 CSA-based 4 25.0% 18 31.6%
 Others 1 6.3% 2 3.5%
Number of HLA matches 0.81
 8/8 7 43.8% 23 40.4%
 ≤7/8 9 56.3% 34 59.6%
Year of transplant 0.76
 1991–1999 8 50.0% 26 45.6%
 2000–2007 8 50.0% 31 54.4%
1

1 missing

2

3 missing